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SYNTHESIS OPTIMIZATION OF  
LIPID-WRAPPED POLYMER NANOPARTICLES 
XI CHEN 
ABSTRACT 
 Nanoparticles (NPs) have become a robust drug delivery platform and are in 
extensive use in the pharmaceutical industry. Lipid-wrapped polymer NPs combine 
the advantages of liposomes and polymer NPs together and exclude some limitations 
of both. This thesis reports how to optimize the synthesis outcome of lipid-wrapped 
polymer NPs by changing the lipid/polymer ratio, 1,2-dioleoyl-sn-glycero-3-
phospho-L-serine(DOPS) composition in lipids and the choice of polymer materials. 
The in vitro stability of the synthesized NPs were tested in 1× PBS buffer in terms of 
size at different time points up to 7-day at room temperature. The lipid-wrapped 
polymer NPs were prepared by one-step nanoprecipitation and self-assembly aided 
by bath sonication for five minutes. We characterized NPs by measuring the 
hydrodynamic diameters and zeta potential through Dynamic Light Scattering (DLS), 
measuring the absorbance through Ultraviolet–visible spectroscopy (UV-Vis) and 
observing the morphology and size distributions through Scanning Electron 
Microscope (SEM). We find the surfactant DOPS ratio has a significant influence on 
size distribution. And NPs with different polymer materials are stable in 1 × PBS 
buffer within 7 days. There is a clear negative correlation between PDI and 
lipid/polymer ratio, which indicates the potential to control PDI by adjusting the 
lipid/polymer ratio. The result of this project has the potential use in precisely 
 
 vii 
controlling the sizes and size distributions of drug-loaded NPs and scaling up the 
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STATEMENT OF PURPOSE   
 The focus of this thesis is to tune the physical properties of lipid-wrapped 
polymer NPs, obtain less than 140 nm sized NPs and narrow NP size distributions. 
NPs were generated through self-assembly and analyzed by different 
characterizations. The effects of surfactant DOPS ratio, choice of polymer materials 





 Nanotechnology is playing an important role in the fields of pharmacy and 
biomaterial [20,37,44]. It has been quickly developing since the 1980s. As the most 
important participant, NPs have become a robust drug delivery platform and have 
been in extensive use. Nanocarrier is one of the non-invasive, time-controlled and 
site-specific approaches for drug delivery in the pharmaceutical industry [13,44]. 
Different types of nanocarriers, such as micelles, liposomes, dendrimers, polymeric 
NPs, have been developed to enhance drug delivery efficacy, drug kinetics, and reduce 
off-target effects[25,44]. Nanocarrier-based chemotherapeutic drugs, either alone or in 
combination with gene therapies, are currently under development with the goal of 
improving clinical outcome[1,2,15]. Abraxane®, Doxil®, Genexol®_PM, Myocet®, 
Depocyt® are successfully marketed products and many others are under clinical 
trials[35]. Connecting with the pandemic COVID-19, nanocarriers constitute a major 
part in the vaccine development [45].  
Among different sorts of nanocarriers, liposomes are widely studied and have 
been used to deliver both hydrophilic and hydrophobic drugs in the past decades [5,46], 
which are spherical lipid vesicles with a bilayer membrane structure consisting of 
amphiphilic lipid molecules[4,5]. Two most common protocols used in the preparation 
of liposomes are extrusion and bath sonication, with each method yielding liposomes 
of different mean sizes and size distributions [24]. Lipid-based carriers show 
advantages such as cost-effective manufacturing and better drug entrapment 




groups to achieve different features, such as being thermally sensitive for fast drug 
releasing [5,22] . A few liposome drug formulations have been approved by the Food 
and Drug Administration (FDA) and are commercially available [1,5,12,20,21]. Liposomal 
formulations not only have benefits[5], but also limitations such as relatively 
complicated fabrication steps, low loading efficiency for hydrophobic drugs, burst 
release kinetics of encapsulated drugs, instability during storage leading to short 
shelf-time, and limited applicable drug delivery[31].  
Another category of nanocarriers, biodegradable polymeric NPs, also called 
for attention due to their bigger capacity of drug loading than liposomes, smaller 
particle size and narrower size distribution[35], tissue penetrating ability, a greater 
variety of preparation methods, availability of various polymers, improved stability 
in biological fluids, versatile drug loading and release profiles[23,29,43]. They can also 
be encapsulated into extracellular vesicles as therapeutic entities[43]. Most polymeric 
NPs such as chitosan-based NPs and PLGA-based NPs are internalized into the cells 
through a mechanism called endocytosis, and are then transported into lysosomes for 
degradation [1, 41]. However, polymer NPs have not yet obtained as much translational 
success as liposomes [5]. Clinical applications of multifunctional polymer-based 
systems are still scarce[20] due to use of toxic organic solvents in the production 
process, poor drug encapsulation for hydrophilic drugs, drug leakage before reaching 
target tissues, polymer cytotoxicity, polymer degradation, and scale-up issues[17,23,31].  
Based on the intrinsic limitations of both liposomes and polymeric NPs, lipid-




characteristics of lipids and architectural advantage of polymer core are combined to 
yield a theoretically superior delivery system, while avoiding some of the limitations 
of the building blocks [3,5,23,35]. This type of hybrid NP has high drug encapsulation 
yield, tunable and sustained drug release profile, excellent serum stability, and 
potential for differential targeting of cells or tissues [3]. Precise control over the drug 
quantity and the release rate in specific parts of the body has numerous advantages 
over conventional drug release, such as enhancing bio-availability and minimizing 
deleterious side effects. These benefits are even more important for patients suffering 
from certain diseases that require multiple dosage regimes, such as chronic diseases 
because they can improve patients' quality of life [20]. Drugs may be incorporated into 
NPs by different methods. Regarding the potential use of NPs in this project, drugs 
are usually incorporated within the NPs during the course of the preparation of NPs 
[45].  
The typical structure of the lipid-wrapped polymer NP is comprised of the 
following components: (i) a hydrophobic polymeric core where poorly water-soluble 
drugs are incorporated with high loading yields; (ii) a lipid layer surrounding the core 
that acts as a highly biocompatible shell and as a molecular fence to promote drug 
retention inside the polymeric core; (iii) a hydrophilic polymer stealth layer outside 
the lipid shell to enhance NP stability and systematic circulation lifetime, which is 
usually the lipid-PEG(Polyethylene glycol) conjugates[5,23] as illustrated in figure 1[5]. 
PEG provides stealth effects against uptake by the immune system[23] and increases 




studies are ongoing to develop stealth coatings for the NPs such that opsonin protein 
adsorption to the NPs and phagocytosis by reticulo-endothelial system (RES, also 
called the MPS, mononuclear phagocyte system) are inhibited [45]. Both PEG chain 
length and lipid/lipid-PEG molar ratio have significant impact on NP stability[5]. 
Besides, surfactants are customarily utilized during NP synthesis to prevent 
aggregation despite their numerous disadvantages[19]. 
 
 
Figure 1 The typical structure of lipid-wrapped polymer NP 
 
There are generally two methods to synthesize the lipid-wrapped polymer 
NPs [3,5,23,32]. One method requires two steps. The polymeric cores and liposomes are 
prepared separately using two independent processes; then the two components are 
combined by direct hydration, sonication, or extrusion to obtain the desired lipid 
shell–polymer core structure[23]. The outcome of this method is lipid bi-layer 
wrapping a polymeric core as seen in figure 1.  
The other method requires only one step: a nanoprecipitation process is 




two different ways of mixing the organic phase and aqueous phase. One way is a 
modification of the emulsion/solvent evaporation method first reported by Gurny et 
al.[23,28]. The polymer and drugs are dissolved in a water-immiscible organic solvent. 
A predetermined amount of lipid is dispersed in water by bath sonication, mechanical 
stirring or heat. The organic phase mixes with aqueous phase, then the mixture is 
sonicated by probe sonicator in an ice bath. The organic phase will disperse into tiny 
nanodroplets, which are nanospheres with lipid layer coats[23].  
In another way utilized in this project, polymer solution is added dropwise 
into the lipid solution. Then external energy is used to expedite the synthesis. The 
outcome is lipid monolayer wrapping a polymeric core as in figure 2[5]. 
 
 
Figure 2 The structure of lipid monolayer NP product synthesized by self-assembly 
 
The physical properties and drug encapsulation characteristics of the NPs 
were controlled and optimized by varying the synthesis parameters[19]. The 




possible errors in operation), easier future scale-up[3,9] and more effective cost[5], etc. 
A major advantage of nanoprecipitation is that stabilizing surfactants commonly 
added during NP synthesis are not required to prevent NP aggregation [19]. Many 
researchers use the nanoprecipitation method to synthesize surface-modified 
polymer NPs as drug carriers, i.e. Trimethylated chitosan (TMC) surface-modified NP 
for brain drug delivery[9]. In the process, the lipid and polymer contact is favored by 
electrostatic interactions, hydrophobic attractions, or van der Waals forces[23]. 
Speaking of the polymeric material choice, Poly (lactide-co-glycolide) (PLGA) 
is a FDA approved biodegradable polymer which has been widely used as a model 
biomaterial for sustained, targeted NP synthesis[1,36] due to PLGA’s clinical 
biocompatibility, tunable biodegradation and resorbable by-products[19,27]. PLGA-
based NPs are applicable for both hydrophilic and hydrophobic drugs, and biological 
therapeutic macromolecules including peptide and protein[1,30]. And PLGA NPs with 
drugs are preferable to traditional oral, intramuscular or intravenous therapies 
because they flow through capillaries, protect molecules from enzymatic degradation, 
enable delivery of non-traditional molecules, are modifiable for receptor targeting 
and can be internalized by cells for cytoplasmic drug delivery [14,16,19]. Furthermore, 
they solubilize hydrophobic drug molecules by encapsulating and separating drugs 
from aqueous physiological environments[19].  
Besides PLGA, Poly-D,L-lactic-acid (PLA) has been extensively used for its 
biocompatibility and biodegradability[38,45]. It is particularly suitable for applications 




available in the market can be differentiated by molecular weight, degree of 
crystallinity, inherent viscosity and proportion of D and L isomers [38]. Nanospheres 
and NPs of PLA and PLGA are generally described as having characteristic dimensions 
smaller than 10 microns in diameter and thus are available for direct endocytosis or 
phagocytosis into leukocytes, monocytes, macrophages and other cells of the reticulo-
endothelial system. Studies to date indicate that PLA and PLGA microspheres 
containing bioactive agents are biocompatible, including when used in therapeutic 
applications in vivo, and they did not exhibit untoward reactions either locally or 
systemically[45]. 
The NP structure design in this study was inspired by the size and lipid 
composition of human immunodeficiency virus type 1(HIV-1), in which cholesterol 
and phospholipids keep a certain ratio. The composition of lipid shell in this project 
is 40% Cholesterol, 60% in total of 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine(DPPC) and 1,2-dioleoyl-sn-glycero-3-phospho-L-serine(DOPS, 
sodium salt). In order to characterize NPs, two different fluorescent dyes are added 
separately in the lipid membranes and polymeric cores of some NPs. Surface moiety 
modification of PLGA-based NPs could greatly enhance the interaction between NPs 
and biological cells, resulting in longer half-life, better cellular uptake and targeting 
effects.  
In this project, drugs were not actually loaded in the NPs. The NPs were not 
designed for in vivo experiments, therefore PEG was not added in the lipids. The 




monolayer shell and polymeric core (Figure 3). NP diameters under 150nm were 
desired in this project because smaller NPs are more easily engulfed by cells [6,19, 34] 
for intracellular drug delivery [18,19,33]. Narrowly unimodal distributed NPs were 
desired in order to minimize complications in filtering, purification and future 
characterization of cellular interactions[19,39]. The NP products were purified right 
after synthesis by three washes. Centrifugation sometimes causes NPs to agglomerate 
into unacceptably large clusters[19,39]. However, purification is critical for cellular 
drug delivery studies because potential therapeutic effects must be attributed to 
drug-loaded NPs[19]. Noteworthily, a novel, nondestructive purification protocol 
involving transient sodium dodecyl sulfate (SDS) adsorption to NPs followed by 
centrifugation and dialysis was claimed to be able to prevent centrifugation-induced 
surfactant-free NP aggregation [19]. 
 
 




Nowadays we have dozens of advanced technologies to characterize NPs. Most 
research uses Dynamic Light Scattering (DLS) to measure the hydrodynamic 
diameters (Z-ave), polydispersity index (PDI) and zeta potentials of NP, given its fast 
and convenient way to operate. PDI can provide additional information about the 
level of agglomeration in solution [8]. Ultraviolet–visible spectroscopy (UV-Vis) can be 
used to measure the absorbance. To obtain more precise results and satisfy different 
characterization needs, sensitive and multiplex optical imaging techniques are 
needed[7]. Scanning electron microscopy (SEM) is usually applied to measure the 
physical dimension of the particles, visualize the size, size distribution, and 
morphology of NPs[5,23,32]. Conventional fluorescence microscopy can prove the 
successful combination of lipids and polymers. Besides, the internal core-shell 
structure and lipid shell thickness are typically measured by transmission electron 
microscopy (TEM) [5, 23].  
Here we report a clear negative correlation between PDI and lipid/polymer 
ratio on lipid-wrapped PLGA NPs. It indicates the potential for us to control and 
predict the PDI by adjusting the lipid/polymer ratio. The condition combination of 
more than 4 μmol/mg lipid/polymer ratio and less than 1 mol% of surfactant DOPS 
easily causes aggregation, significantly increases PDI, and results in experiment 
failures. The choice of PLA or PLGA as polymer material doesn't significantly affect 
the short-term in vitro stability in 1× PBS buffer of lipid-wrapped polymer NPs with 




MATERIALS AND METHODS 
1. Materials 
Poly(D,L-lactide) high molecular weight(PLA HMW), ester terminated, R207S, 
MW 209,000[38] and Poly (D,L-lactide-co-glycolide) Lactide:Glycolide(PLGA) 50:50, 
ester terminated, RG503, MW 24,000-38,000 were obtained from Sigma-Aldrich (St 
Louis, MO).  
Cholesterol, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine(DPPC) and 1,2-
dioleoyl-sn-glycero-3-phospho-L-serine(DOPS, sodium salt) were purchased from 
Avanti Polar Lipids (Alabaster, AL).  
Other reagents including anhydrous ethanol, Milli-Q water,  4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) powder, NaCl powder , 
acetonitrile, Poly-L-lysine(0.1% (w/v) in H2O) and 10× Phosphate-buffered 
saline(PBS) buffer were obtained from Sigma-Aldrich (St Louis, MO). Micro slides for 
SEM images were purchased from Corning Incorporated (Corning, NY). 
 
2. Liposome preparation 
Cholesterol, DPPC and DOPS with specified mol% were mixed in a round-
bottom flask. The total amounts of lipids were 0, 1, 2, 4, and 6 μmol. After evaporating 
the organic solvent (chloroform) using Rotavapor (BüCHI, R-200, Brinkmann 
Instruments, Westbury, NY) at 30 ℃ for 10 min, a thin uniform lipid layer formed on 
the bottom. The flask was then put on vacuum overnight. Next, 1.2 mL of 20 mM 




agitation. Under Argon protection, liposomes were made of the lipid mixture by probe 
sonication (120 Sonic Dismembrator, Fisher Scientific, Waltham, MA).  
 
3. Lipid-wrapped Polymer NP synthesis 
The prepared liposome solution was mixed with 4 wt% ethanol aqueous 
solution for 15 minutes. The polymers were dissolved in acetonitrile to make a 
solution with a concentration of 2.5 mg/mL. The polymer solution was then added 
into the liposome solution dropwise. The volume ratio of organic phase/aqueous 
phase in the mixture is always 1/10. To synthesize the lipid-wrapped polymer NPs, 
the mixture was sonicated in a bath sonicator for 5 min under room temperature 
(Branson Ultrasonics 5510, Danbury, CT). The lipid-wrapped polymer NPs were 
washed 3 times (15 min per washing cycle) to remove organic solvent and free lipids 
using Amicon Ultra-4 centrifugal filter with molecular weight cutoff 10 kDa (Millipore 
Sigma, Burlington, MA).   
 
4. Characterization  
4.1 Size distribution and zeta potential measurements 
The hydrodynamic diameters (Z-ave) and polydispersity (PDI) of liposomes 
and the lipid-wrapped polymer NPs after synthesis (before and after washing) were 
measured by dynamic light scattering (DLS) in Zetasizer (ZEN3690, Malvern, 




with Milli-Q water. Liposomes were diluted 10 times in water for size measurements. 
Lipid-wrapped polymer NPs were measured without dilution before washing, and 
were diluted 10 times in water for measurements after washing. The zeta potentials 
of the lipid-wrapped polymer NPs after washing were measured in 10 mM NaCl 
solution (Zetasizer).  
 
4.2 Morphology and size  
Samples for SEM were incubated on the Poly-L-lysine-treated microscope 
cover glass substrates for 20 min. The glass substrates were washed by water drops 
three times. Argon flowed around until the glass substrates seemed dry. Samples 
were then put in the fume hood for overnight drying. All samples were Au-sputtered 
before being subjected to imaging. SEM images were generated on a Zeiss Supra 40 
VP SEM with 5 eV EHT.  
 
4.3 Absorbance measurements 
Samples were diluted 8 times in Milli-Q water. The absorbance measurements 
at λ=500 nm of selected samples were completed on the Spectronic 200 UV-vis 





4.4 Stability measurements   
To monitor the stability of lipid-wrapped polymer NPs, the particle sizes and 
PDI were measured using a Zetasizer at different incubation time points, including 0 
min (right after the mixture of NP and PBS), 10 min, 30 min, 1h, 24h and 7-day. The 
NPs were incubated in 1 × PBS buffer (pH 7.4) at room temperature. Stock solution 
for incubation was made by diluting the product 10 times in 1 × PBS buffer. The 
samples for DLS measurements were made by diluting the stock solution 10 times in 
water.  
 
5 Experiment design 
In this project, three independent variables were explored: lipid/polymer 
ratio, DOPS ratio and the choice of core polymer materials. The incipient parameters 
are 1 μmol lipids with different ratios of DOPS and different 1mg core polymer 








1μmol 2μmol 4μmol 6μmol 
0 √    
1 √□≋   √⋆ 
3 √≋ √≋ √≋ √≋ 
10 √≋   √ 




0(core only) 1μmol 2μmol 3 μmol 4μmol 6μmol 
0 √ √ √  √⋆ √⋆ 
1  √≋    √⋆ 
3 √ √≋ √  √ √ 
6  √□ √≋ √≋ √≋ √□ 
10 √ √    √ 
Table 2 Experiment summary of PLGA NPs 
 
Meanings of symbols: 
√, accomplished experiments 
⋆, failed experiments  
□, samples were characterized by SEM 




RESULTS AND DISCUSSION 
1. Morphology and size (SEM images) 
 
Figure 4 SEM images and size distribution analysis of PLA HMW NPs with 1%DOPS 
and 1 μmol/mg lipid/polymer ratio. (a) (b) (c) are SEM images. Particles have mean 
size 45.89nm and standard deviation (SD) 5.54nm; PDI=0.12 (SEM Images in this 






Figure 5 SEM images and size distribution analysis of PLGA NPs with 6%DOPS and 6 
μmol/mg lipid/polymer ratio. (a) (b) are SEM images. Particle size: 95.07±18.58nm, 
PDI=0.20 (c) is the size distribution analysis. Samples had a low concentration so 






Figure 6 SEM images and size distribution analysis of PLGA NPs with 6%DOPS and 1 
μmol/mg lipid/polymer ratio. (a) (b) (c) are SEM images. Particle sizes 
131.7±32.9nm; PDI=0.25 (d) is the size distribution analysis. 
 
2. Absorbance measurements 




















Absorbance 0.24 0.27 0.15 0.15 0.05 0.07 














Absorbance 0.04 0.12 0.03 0.06 0.09 
Table 4 Absorbance of lipid-wrapped PLGA NPs (diluted 8 times) 
 
3. The effects of surfactant (DOPS) 
Surfactant DOPS [11] was added to provide negative charges on the outside 
surface, in order to prevent aggregation. But some NPs aggregated during the 
washing steps. The reasons should be insufficient surface charges or inappropriate 
lipid-polymer ratios. In Table 1 and 2, the failures happened when ≤1% DOPS was 
added in the samples with ≥ 4 μmol/mg lipid/polymer ratio. Therefore, NPs tended 
to gather and aggregate in centrifugation without DOPS. In the later stage of 
experiment design, the 0%DOPS condition was not in consideration.  
 
4. PLA HMW & PLGA as core material 
The in vitro stabilities of PLA HMW and PLGA products were compared in 
Figure 4. They were synthesized under the same conditions with 3%DOPS and 6μmol 




industry, both polymers are stable in 1 ×PBS buffer in short terms (up to 7-day). 
Noteworthily, the PDI of both NPs kept increasing with time.  
 
 
Figure 7 In vitro stability comparison of PLA HMW NPs and PLGA NPs, with 
3%DOPS and 6 μmol/mg (lipid/polymer ratio) in 1 × PBS buffer 
 
5. Lipid/polymer ratio 
As mentioned in the experiment design section, the incipient ratio of lipid and 
polymer was 1 μmol/mg. When the ratio of lipid/polymer increased to 4μmol lipid/ 
1mg polymer or higher, failures began happening on products with ≤ 1mol% DOPS.  
When analyzing PLGA NPs with 3%DOPS, there is no clear linear positive or 





Figure 8 Size and zeta potential of 3%DOPS-PLGA NPs 
 
However, the PDIs of PLGA NPs with 3% DOPS decreased as the lipid/polymer 
ratio increased. The clear negative correlation between PDI and lipid/polymer ratio 
shows a potential of controlling and even predicting the PDI by adjusting the 











The choice of PLA or PLGA as polymer material doesn't significantly affect the 
short-term in vitro stability of lipid-wrapped polymer NPs in 1 × PBS buffer. Its effect 
on size is to be explored further. The condition combination of ≥ 4 μmol/mg 
lipid/polymer ratio and ≤ 1 mol% of surfactant DOPS easily causes aggregation, 
significantly increases PDI, and results in experiment failures. PDI was found to hold 
a negative correlation with the lipid/polymer ratio (up to 6 µmol/mg) on lipid-
wrapped PLGA NPs. It indicates a potential to control and even predict PDI by 
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